Background: inhibition of acetylcholinesterase (AChE) has been a effective treatment for Alzheimer's disease (AD). Octohydroaminoacridine, a new AChE inhibitor, is a potential treatment for AD. Method: we conducted a multicenter, randomised, double blind, placebo-controlled, parallel-group Phase II clinical trial to investigate the effects of octohydroaminoacridine in patients with mild-to-moderate AD. Patients were randomised to receive placebo thrice daily, octohydroaminoacridine 1 mg/thrice daily (TID) (low-dose group), 2 mg/TID (middle-dose group) or 4 mg/TID (high-dose group). Doses in the middle-dose and high-dose group were titrated over 2-4 weeks. Changes from baseline to Week 16 were assessed with the AD Assessment Scale-Cognitive Subscale (ADAS-cog), Clinician's Interview-Based Impression of Change Plus (CIBIC+), activities of daily living (ADL) and the neuropsychiatric inventory (NPI). ADAS-cog was the primary end point of the study. A two-way analysis of covariance and least squares mean t-test were used. Results: at Week 16, the changes from baseline in ADAS-cog were 1.4, −2.1, −2.2 and −4.2 for placebo, low-, middle-and high-dose groups, respectively. Patients in the high-dose group had better performance in CIBIC+ and ADL scores at the end of the study. There was no significant difference in the change in NPI score among the groups. The effects of octohydroaminoacridine were dose dependent, and were effective within 16 weeks of treatment. No evidence was found for more adverse events that occurred in different drug groups than placebo group.
Introduction
Alzheimer's disease (AD) is a progressive dementia that affects millions of elderly people worldwide [1, 2] . Cholinergic neuron degeneration is the most prominent neurochemical disturbance in AD patients and is thought to impair memory and related functions [3] . Inhibition of acetylcholinesterase (AChE) is one effective treatment for AD through inhibiting the breakdown of released acetylcholine to enhance surviving cholinergic neurotransmission. Tacrine was the first AChE inhibitor approved by the US Food and Drug Administration to treat AD; unfortunately, it failed because of unacceptable side effects including hepatotoxicity [4] [5] [6] . Other AChE inhibitors have been widely used and improve cognitive function in patients with AD; however, all AChE inhibitors showed dose-dependent side effects, especially in the digestive system [7] [8] [9] . Octohydroaminoacridine (9-Amino-1, 2, 3, 4, 5, 6, 7, 8-octahydroacridine and C 17 H 24 N 2 O 4 ,), a novel synthesised cholinesterase inhibitor, could potentially inhibit both AChE and butyrylcholinesterase (BuChE).
Octohydroaminoacridine is more likely to choose AChE [10] . In preclinical investigations, octohydroaminoacridine showed greater specificity for BuChE and a longer duration of action [10] . The BuChE:AChE binding ratios in human for a clinical dose of Donepezil, Galantamine, Rivastigmine and octohydroaminoacridine were 189, 9, 1.1 [10] and 0.1 [11, 12] , respectively. The BuChE:AChE binding ratio of octohydroaminoacridine is the lowest available in this class of agents, indicating that octohydroaminoacridine possesses high central versus peripheral cholinomimetic specificity [11, 12] . The chemical structure of octohydroaminoacridine is related to that of tacrine, but has been modified to reduce the toxicity to liver. In a Phase I study of octohydroaminoacridine, no evidence of clinically significant adverse events or hepatotoxicity were observed [13] .
The present Phase II study was undertaken to evaluate the efficacy and safety of octohydroaminoacridine at dosage levels of 3, 6 and 12 mg/day versus placebo in patients with mild-to-moderate AD, and to investigate the optimal dose for Phase III clinical studies.
Patients and Methods

Patients
This study was registered as a clinical trial with ClinicalTrials. gov registry number NCT01569516 (www.clinicaltrials.gov). The study included male and female outpatients between 50 and 85 years old diagnosed with mild-to-moderate probable AD. Female patients were either at least 2 years postmenopausal, or had accepted sterilisation surgery prior to entry. Probable AD was diagnosed according to the National Institute of Neurological and Communicative Disorders and Stroke/AD and Related Disorder's Association (NINCDS/ ADRDA) [14] criteria. Mild-to-moderate AD was documented on the basis of the score on the Mini Mental State Examination (MMSE) [15, 16] . AD subjects who had not been educated exhibited MMSE scores from 5 to 16, those with elementary school education exhibited MMSE scores from 8 to 21 and those with higher than middle school education exhibited MMSE scores from 11 to 25. The absence of depression was documented on the basis of a score of 10 or less on the Hamilton Rating Scale for Depression (HAMD) [17] . Brain computed tomography (CT) or magnetic resonance imaging (MRI) scan within the previous year excluded other structural brain disease, and neurologic examination showed no significant abnormalities. AD patients recorded scores of <4 on the Hachinski Ischaemia Scale (HIS) [18] and showed no history of significant systemic or psychiatric conditions, or traumatic brain injuries that could compromise brain function. Patients were able to complete the test procedure, had the audiovisual and physical abilities to complete the neuropsychological measures, and had a stable caregiver who spent more than 2 hours a day or more than 14 hours per week with the patient.
Exclusion criteria
Patients were excluded if they had evidence of any dementia other than AD, such as vascular dementia, dementia with Lewy bodies, frontotemporal dementia or Parkinson's disease. History of stroke or cerebrovascular disease, bone marrow transplantation, major psychiatric disorder, serious lack of folic acid or Vitamin B12 and history of alcohol or drug abuse were also causes of exclusion from the study. Patients who were syphilis antibody positive, had evidence of thyroid dysfunction or mechanical intestinal obstruction, and had been treated for AD within the 4 weeks prior to randomisation were excluded. Any sudden onset of early dementia with gait disorders, seizures or behavioural changes, and clinical manifestations of focal neurological damage (hemiparesis, sensory loss and visual field defect) or early extra pyramidal tract damage was a reason for exclusion. Patients with a resting pulse less than 60 and no evidence of liver or renal disease at screening visit were excluded. If patients had the status mentioned above, they were excluded in screening. During the screening period, patients were also excluded if any of the following were S. Xiao et al.
observed: significant focal lesions confirmed by MRI examination; leukoencephalopathic areas greater than 25% of total amount of alba (moderate and severe leukoencephalopathy); more than two lacunar infarct lesions in the thalamus, hippocampus, entorhinal cortex, perirhinal cortex, cortex and/or subcortical grey matter nuclei; MRI indicating possible cognitive impairment or dementia other than AD.
Study design
This 16-week Phase II clinical study was undertaken in 16 centres in China from May 2011 through August 2013, utilising a multicenter, randomised, double blind, placebocontrolled and parallel-group design. There were 4 weeks of washout phase from −4 weeks (screening visit) to 0 weeks (randomisation visit). Participants were randomly assigned 1:1:1:1 to low, middle and high dose of octohydroaminoacridine or to a placebo group. The low dose of octohydroaminoacridine group was 1 mg thrice daily (TID, 3 mg/day). The middle-dose group was 1 mg TID in the first 2 weeks (3 mg/day) and increased to 2 mg TID from 3 to 16 weeks (6 mg/day). The high-dose group was 1 mg TID for the first 2 weeks (3 mg/day), increased to 2 mg TID from 3 to 4 weeks (6 mg/day) and then increased to 4 mg TID from 5 to 16 weeks (12 mg/day). Treatment was assigned by use of a randomised block design with block sizes of four groups, via a central randomisation system (by internet). The randomisation sequence was created by SAS 9.2 software and was used by the central randomisation system to allocate treatment assignment. At randomisation, patients were stratified according to the degree of disease (mild or moderate) and level of education. Patients and investigators were masked to treatment assignment. The study procedures were undertaken in the conduct centres and always in the same sequence (i.e. neuropsychological evaluation, physical examination and collection of blood samples). MMSE, HIS and HAMD were assessed only at the screening visit and the randomisation visit.
According to the Chinese guidelines for clinical trials, Phase II study should not include less than 100 cases. However, the experiment was set up with a low-, middleand high-dose experimental group and a placebo control group, 60 cases in each group. To account for an expected withdrawal rate of 20% of cases, we included 72 cases in each group, for a total of 288 cases.
The primary outcome assessment was the AD Assessment Scale-Cognitive subscale 12 items (ADASCog/12) [19] ; changes from baseline were the primary outcome measures. The scale was completed by a trained and experienced neurologist, psychiatrist, neuropsychologist or another trained and experienced person approved by Changchun Huayang High-tech Co., Ltd. ADAS-Cog assessments were performed at the screening visit (−4 weeks), the randomisation visit (0 weeks), and at 8, 16 weeks and at early withdrawal where applicable.
Secondary outcome measures were the Clinician's Interview-Based Impression of Change Plus (CIBIC+) [20] , activities of daily living (ADL) [21, 22] and the neuropsychiatric inventory (NPI) [23] [24] [25] tests. The independent rater who assessed CIBIC+ was a trained and experienced neurologist, psychiatrist, neuropsychologist or another trained and experienced person approved by Changchun Huayang High-tech Co., Ltd. CIBIC+ assessments were performed at the screening visit (−4 weeks), the randomisation visit (0 weeks), and at 8, 16 weeks and at early withdrawal where applicable. ADL was conducted by interviewing the caregiver. ADL is also the general second outcome of clinical trials of new drug for AD treatment. We used the total score of ADL in the statistical analyses. The NPI is an assessment of the frequency and severity of behavioural disturbance in dementia. ADL and NPI assessments were performed at the screening visit (−4 weeks), the randomisation visit (0 weeks), and at 8 and 16 weeks.
The study protocol was approved by the institutional review board at each participating site, and all participants provided written informed consent; written informed consent was obtained from the patients or their legally authorised representatives or caregivers.
Safety assessments
Safety evaluations throughout the study comprised vital signs, physical examination and laboratory tests. Adverse events were monitored through scheduled questioning. All events reported by the patients, or noticed by the caregivers or investigators, were recorded together with the date of onset and outcome, severity and relationship to the trial medication.
Haematology analysis and serum biochemical liver function were performed at the randomisation visit (0 weeks), and at 1, 2, 3, 4, 8, 12 and 16 weeks visits. Urine and stool analysis, kidney function and cholesterol and lipids, coagulation tests and electrocardiography were performed at the randomisation visit (0 weeks), and at 4, 8 and 16 weeks visits. Fasting serum glucose, vitamin B12 and folate levels, syphilis antibodies and thyroid function were assessed at the screening visit only (−4 weeks).
Statistical analysis
The efficacy analyses of estimated between-group differences in clinical outcomes (primary outcome: ADAS-cog; secondary outcome: CIBIC+, ADL and NPI) from baseline to Week 16 were performed on data from the modified intention-to-treat (ITT) population. The ITT population in our study are the subjects who took their medicine at least once following randomisation. The primary outcome and the secondary outcome analyses did not conduct the missing data imputation. The change in clinical outcomes from baseline to Week 16 were compared between these four groups using a two-way analysis of covariance. When there were significant differences between groups, we calculated Efficacy and safety of octohydroaminoacridine in AD the least squares mean (LSM) of change in clinical outcome of each group. We compared the difference between every treatment group and placebo group by test. Safety analyses were based on the safety population which consisted of all randomised who received at least one dose of double blind study medication. Safety analysis also included summary listings of adverse events, with Fisher's exact test used for comparisons.
All analyses were performed with the use of SAS software, version 9.2. The significance level was set at P ≤ 0.05. All statistical testing was two sided.
Results
Completion rates and baseline characteristics
A total of 284 patients underwent randomisation in this multicenter, randomised, double blind, placebo-controlled parallel-group Phase II clinical study. The most common reason for not proceeding to randomisation was excluding results on brain CT or MRI examination. Completion rates were 79.2% for the placebo group, 80.3% for the low-dose group, 81.4% for the middle-dose group and 80.3% for the high-dose group. The most common reason for early withdrawal was participants not agreeing to continue the trial.
There were no significant differences among these four groups with regard to baseline characteristics in the modified ITT population (Table 1 ). There were no significant differences among groups in ADAS-Cog (P = 0.69), CIBIC+ scores (P = 1.00), ADL (P = 0.50) and NPI (P = 0.91) at baseline.
Changes in primary and secondary outcome measures
Changes in ADAS-cog score from baseline to Week 16 indicated that there were significant differences among the groups (Table 2) . Moreover, the LSMs of changes in ADAS-cog score were 1.4, −2.1, −2.2 and −4.2 in placebo, low-, middle-and high-dose groups, respectively (P < 0.01 for the comparison of all octohydroaminoacridine groups with the placebo group).
We found significant differences among the groups in CIBIC+ scores (P = 0.011, Supplementary data, Appendix 3, are available at Age and Ageing online) and in ADL scores (P < 0.01, Supplementary data, Appendix 2, are available at Age and Ageing online), but not in NPI scores (P = 0.99, Table 3 ). ADL score, the LSM changes were −0.98, 0.00, 0.61 and 1.21 for placebo, low-, middle-and high-dose groups, respectively. The ADL scores decreased more in middle and high groups (P < 0.01 compared with placebo group).
Safety
Adverse events occurred in 84.1, 51.5, 72.7 and 55.7% of the placebo, low-, middle-and high-dose groups, respectively (P < 0.001). For serious adverse events, the incidence rates were 2.9, 2.9 and 4.6% in the placebo, low-dose and middle-dose groups, respectively. No serious adverse events occurred in the high-dose group. There were significantly statistical differences for adverse events among these four groups (P < 0.01). The frequency of laboratory abnormalities in placebo group was significantly higher than the three treatment groups (33.3% versus 13.2%, 16.7% and 10.0%; P < 0.01).
Discussion
In this study, octohydroaminoacridine improved cognitive function among patients with mild-to-moderate AD. The effects of octohydroaminoacridine were dose dependent, and were effective within 16 weeks of treatment. The rate of adverse events in treatment groups was not dose dependent. The LSM difference of changes in ADAS-Cog scores between the high dose and placebo groups was 3.5 (−2.1-1.4, P < 0.01, Table 2 ). In the high-dose group, the ADAS-Cog scores improved 2.1 from baseline to 16 weeks. Furthermore, octohydroaminoacridine treatment improved patients' functional abilities and behaviour according to the results of CIBIC+ and ADL tests. The effects of previously used cholinesterase inhibitors on ADL are unclear [26] . Studies on donepezil have neither reported functional benefits [7, 27, 28] nor shown any benefit if basic ADL (selfcare tasks such as dressing and personal hygiene) are removed from the analysis [29] . Rivastigmine has shown favourable effects on daily activities [9, 30] , although the validity of these results has been questioned [26] . The Phase II study give us effective information about the effect of octohydroaminoacridine on ADAS-Cog, CIBIC+ and ADL. These results should be confirmed in a Phase III clinical study.
The current study provides evidence of the efficacy of octohydroaminoacridine in alleviating the core cognitive and functional symptoms of patients with mild-to-moderate AD over 16 weeks. Octohydroaminoacridine was effective on each of the measures of efficacy investigated, reflecting improvements in cognition as rated by psychometricians, global functioning as rated by an independent clinician and ADL as rated by a caregiver.
There was no evidence that the treatment group was more likely to experience adverse events compared with placebo, in contrast to other AChE inhibitors [8, 9] . The most common adverse events seen were related to cardiovascular function and gastrointestinal. Most were mild and short-lived, and were observed after increasing octohydroaminoacridine doses. There was no evidence that octohydroaminoacridine compromised cardiovascular function in these elderly patients, many of whom had concomitant cardiovascular disease. The overall incidence of serious adverse events was similar in all three treatment groups. Despite the age of the patients, the high incidence of coexisting illnesses, and the use of concomitant drug treatment, octohydroaminoacridine produced no clinically relevant changes in laboratory tests, electrocardiograms, on physical examination, or in vital signs except for a small, statistically significant decrease in mean body weight at higher doses. Only two patients discontinued treatment because of adverse events experienced when taking octohydroaminoacridine.
One of main aims in this Phase II clinical study was to investigate the drug dose for further clinical study. The highest dose of octohydroaminoacridine used had the greatest beneficial effect on cognitive function and behaviour in The difference among groups were compared using univariate statistics of ANOVA for the normal distribution and homogeneity of variance data. Non-normal distribution continuous data were compared using the Kralkal-Wallis rank sum test for the difference among the groups. The difference among groups were compared using univariate statistics of ANOVA for the normal distribution and homogeneity of variance data. Non-normal distribution continuous data were compared using the Kralkal-Wallis rank sum test for the difference among the groups.
Efficacy and safety of octohydroaminoacridine in AD patients with mild-to-moderate AD. Moreover, this high dose of drug was not associated with an increased incidence of adverse events. This is the first Phase II clinical study for octohydroaminoacridine in AD. The results of this study showed that the highest dosage of the drug has the greatest beneficial effect on cognition and daily living. Furthermore, compared with the low-dose group, the incidence of adverse events in the high-dose group was not significantly increased. Therefore, the results indicate that the high dose can safely be explored in the further study.
In conclusion, our study indicates that daily treatment with octohydroaminoacridine significantly improved cognitive function and behaviour among patients with mild-to-moderate AD. We must acknowledge that the short duration of this study is an important limitation. Further clinical studies are needed to further explore the safety and efficacy of this drug for general treatment and therapy with longer duration.
Key points
• Octohydroaminoacridine is a novel acetylcholinesterase Inhibitor and has a potential treatment for Alzheimer's disease (AD).
• The highest dosage (4 mg/thrice daily (TID)) of the octohydroaminoacridine has the greatest beneficial effect on cognition, daily living and behaviour in patients with mildto-moderate AD according to the results of 16-week Phase II clinical study.
• The incidence of adverse events in the high-dose group (4 mg/TID) was not significantly increased than the lowdose group in the Phase II clinical study.
Supplementary data
Supplementary data are available at Age and Ageing online.
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